Medtronic says it's not affected by the latest federal crackdown on tax inversions

Due to rumbles of an impending tax inversion deal between Pfizer ($PFE) and Allergan ($AGN), the feds are once again trying to make life difficult for companies like Ireland's Medtronic ($MDT) that moved their headquarters abroad to gain tax advantages. Medtronic said the latest rule changes won't have a material financial impact on the company. A previous rule change did not squash its $50 billion deal to acquire Covidien, though it did force the company to take on more debt than anticipated to finance the transaction. More

Suggested Articles

The FDA will be working with government and public-private partners to distribute and evaluate 3D designs and models.

The FDA issued a wide-ranging emergency policy allowing alternative devices to be used as potentially lifesaving ventilators amid new shortages.

Hospitals in the New York City area are turning to a private distributor to airlift millions of protective masks out of China.